Health Care · Health Care Equipment · US stock · price as of 16 Oct 2026
Key indicators
Price
$152.64
52-week range
$81.17 – $166.25
Market cap
$17.0B
P/E (trailing)
73.2×
EV / EBITDA
24.9×
Free-cash-flow yield
3.3%
Dividend yield
0.2%
Revenue (last 12 months)
$2.9B
Revenue growth (3y a year)
−4.8%
Operating margin
12.3%
Return on invested capital
3.4%
Net debt / EBITDA
2.8×
Fair value
Blended fair value$56.78 range $44 – $57
Versus priceOvervalued−63% to fair value
Peer multiples
$58.83
Fundamentals-adjusted multiple
$54.72
10-year DCF (market-scaled)
$15.62
Earnings power value (floor, not blended)
$29.45
Model uncertainty
High
X-Ray Score
24/ 100 · High confidence · ahead of 5% of sector peers
Valuation15
Growth19
Profitability25
Financial health39
Dividends29
Five-year price chart navy: price · brown: 200-day average · blue band: fair value range
Executive summary
Revvity is a life sciences and diagnostics company that was formerly known as PerkinElmer. It supplies instruments, reagents, software and services used by researchers and drug developers, and it provides diagnostic tests including newborn and prenatal screening and immunodiagnostics. Customers are pharmaceutical and biotechnology firms, academic laboratories, hospitals, clinical laboratories and public health bodies. The business is organised into life sciences and diagnostics segments.
Revenue of $2.9 billion over the last twelve months comes from recurring reagents and tests, instruments and software. Revenue has changed at -4.8% a year across the last three years. The operating margin is 12.3%, the business earns 3% on the capital invested in it, and net debt is 2.8 times EBITDA. The dividend yield is 0.2%.
StocksXray gives Revvity, Inc. an X-Ray Score of 24 out of 100 (high confidence), ahead of 5% of the S&P 500 stocks in its sector. Its strongest lens is financial health (39) and its weakest is valuation (15).
Our fair value blend is $56.78 (range $43.81 to $56.78). At $152.64 the stock trades 169% above that blend, so the label is "Overvalued" with high model uncertainty. Fair value is a range, not a price target.
XStocksXray
Revvity, Inc. (RVTY)
Valuation history multiples at each fiscal year-end price; the last column uses today's price and the last twelve months
FY2022
FY2023
FY2023
FY2024
FY2025
Now
Price
$198.75
$138.87
$108.50
$111.45
$96.56
$152.64
Market cap
$23.2B
$17.6B
$13.5B
$13.7B
$11.3B
$17.0B
P/E
24.6×
30.9×
19.5×
50.7×
46.6×
73.2×
EV / revenue
7.2×
6.5×
5.8×
5.7×
4.7×
6.6×
EV / EBITDA
17.6×
18.4×
21.6×
20.2×
17.8×
24.9×
Price / free cash flow
17.5×
29.5×
1,367.3×
25.3×
22.1×
30.5×
Free-cash-flow yield
5.7%
3.4%
0.1%
4.0%
4.5%
3.3%
Price / book
3.2×
2.4×
1.7×
1.8×
1.6×
2.4×
Dividend yield
–
0.20%
0.26%
0.25%
0.29%
0.18%
Fundamentals checklist ● 1 Good · ● 4 Average · ● 10 Bad · each check graded against the sector
Cash quality
Earnings backed by cash−3.2%Average
Free-cash-flow yield3.3%Bad
Risk models
Altman Z score4.0×Average
Piotroski F-Score5 of 9Bad
Growth
EPS growth (3y)−22.8%Bad
Free-cash-flow growth (3y)−5.0%Bad
Revenue growth (3y)−4.8%Bad
Growth consistency80%Bad
Balance sheet
Current ratio1.8×Good
Net debt / EBITDA2.8×Average
Interest cover3.8×Bad
Valuation
Fair value vs price0.4×Bad
EBIT / EV yield1.9%Bad
Profitability
Return on invested capital3.4%Bad
Operating margin12.3%Average
XStocksXray
Revvity, Inc. (RVTY)
Financials US$ millions, from SEC filings; last column is the last twelve months
Income statement
FY22
FY23
FY23
FY24
FY25
LTM
Revenue
3,828
3,312
2,751
2,755
2,856
2,912
Gross profit
2,434
1,990
–
–
–
–
Operating income
1,258
743
301
347
357
359
Net income
943
569
693
270
241
238
Diluted EPS ($)
8.08
4.50
5.55
2.20
2.07
2.09
Free cash flow
1,325
594
10
542
509
558
Gross margin
63.6%
60.1%
–
–
–
–
Operating margin
32.9%
22.4%
10.9%
12.6%
12.5%
12.3%
Net margin
24.6%
17.2%
25.2%
9.8%
8.4%
8.2%
Balance sheet
FY22
FY23
FY23
FY24
FY25
LTM
Total assets
15,001
14,130
13,565
12,392
12,168
12,046
Cash
603
454
913
1,163
920
1,023
Total debt
4,984
4,394
3,900
3,151
3,220
3,205
Equity
7,141
7,383
7,873
7,667
7,250
7,229
Dividend per share ($)
–
0.28
0.28
0.28
0.28
0.28
Revenue and net income US$ billions: navy revenue, teal net income
Every number comes from SEC filings, end-of-day prices and the StocksXray models described on the methodology page. The X-Ray Score ranks each metric against the company's own sector. Fair value blends three models and carries a typical error of about 40%, so treat it as a range. Analyst ratings, price targets and earnings-call summaries are not part of this report. Educational research, not financial advice; read the disclaimer.